Name: Biotechnology Valuation & Investing (en Inglés)
Price: 1243.78 MXN
Availability: InStock
Author: Hsu, Jason ; Iliopoulos, Dimitrios
ISBN: 9781790407484

Envío gratis

portada Biotechnology Valuation & Investing (en Inglés)

Formato

Libro Físico

Autor

Jason Hsu

Dimitrios Iliopoulos

Editorial

Independently Published

Año

2019

Idioma

Inglés

N° páginas

166

Encuadernación

Tapa Blanda

Dimensiones

21.6 x 14.0 x 1.1 cm

Peso

0.27 kg.

ISBN13

9781790407484

Categorías

Emprendimeinto

Biotechnology Valuation & Investing (en Inglés)

Jason Hsu (Autor) · Dimitrios Iliopoulos (Autor) · Independently Published · Tapa Blanda

Libro Nuevo

$ 1,243.78

$ 2,072.97

Ahorras: $ 829.19

40% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Miércoles 17 de Julio y el Jueves 25 de Julio.

Lo recibirás en cualquier lugar de México entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Biotechnology Valuation & Investing (en Inglés)"

The selection of biotech stocks for investment is more difficult compared with the selection of other stocks and industries that possess historical data, since biotechnology is a recently new science. In the first edition of this book, we described the crucial parameters for the valuation of an early stage biotech company without a drug in the market. In this edition, we analyze novel financial models that can value stocks of biotech companies with products in the market or products under development (in pre-clinical and clinical studies). All of these parameters should be helpful to potential new investors when creating a stock portfolio that includes highly promising biotech companies. Our strategy of selecting highly promising stocks based on all parameters described in this book and of performing a basic financial modeling analysis with DFC and/or real options valuation models has proven very successful, as this strategy provides returns higher than 100% in most cases. In the first edition of this book, based on our strategy, we suggested that Juno Therapeutics and Kite Pharma were "hot" stocks. At that time, Kite's stock was $50.19, while Juno's stock was $54.21. Since then, Kite's stock reached $179.79, with the company acquired by Gilead for $11.9 billion, while Juno's stock reached $86.96, with the company acquired by Celgene for $9 billion. Furthermore, Moderna Therapeutics, a private company that we valued at $5.5 billion in 2016 based on our real options financial model, today has a $7.5 billion valuation. This newly revised and expanded version was written to help investors in the selection of biotech stocks based on different scientific and financial criteria.